The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1261 articles
Clinical trials across the cardiovascular-kidney-metabolic spectrum demonstrate kidney protective effects of incretin-based therapies. Multiple studies show GLP-1RAs and dual GIP/GLP-1RAs reduce kidney disease progression, albuminuria, and kidney failure risk in patients with type 2 diabetes and chronic kidney disease.
Mindy Kaling appeared remarkably transformed at the pre-Golden Globe Awards event, highlighting her 40lb weight loss through healthy habits. She discussed evolving fitness views, while details on GLP-1 drugs and other attendees filled the night. The ceremony honored stars like Sarah Jessica Parker and Helen Mirren.
GLP-1 medications have evolved beyond endocrinology to influence medical aesthetics, creating a hybrid market where pharmaceuticals meet consumer identity. This shift highlights opportunities in MedSpas and compounding pharmacies but also poses significant risks. Manufacturers must adapt to maintain control in this evolving landscape.
The introduction of a GLP-1 pill for weight loss marks a significant advancement in obesity treatment, offering an oral alternative to injections like Wegovy. Experts highlight its potential for broader access, though it shares similar expenses, adverse effects, and the necessity for a healthy lifestyle. Key details cover efficacy, timelines for results, pricing, side effects, dosing requirements, and upcoming options.
A Canada-based online pharmacy service has started supplying Novo Nordisk's diabetes drug Ozempic, sourced from India, to US patients seeking affordable options. The pre-filled pens are available in various doses with a valid prescription and free shipping. This move responds to rising US drug prices and growing consumer interest in international pharmacy services.
As the new year begins, many focus on health objectives like shedding pounds or improving nutrition. Calocurb offers a natural, over-the-counter alternative to GLP-1 injections for appetite control. Discover its workings, dosage, side effects, and pricing to see if it fits your lifestyle.
Roche has invested $100 million in a licensing agreement with Structure Therapeutics to protect its GLP-1 portfolio from patent challenges. The deal covers CT-996, an oral GLP-1 medication acquired from Carmot, and includes royalties on future sales. Analysts highlight how this move reinforces Structure's strong intellectual property in GLP-1 agonists.
The United States now offers an additional avenue for weight reduction as Novo Nordisk introduces its Wegovy oral medication across the country. This daily tablet, featuring semaglutide, represents the initial and sole GLP-1 pill for adults, simplifying obesity management without injections. Clinical studies indicate notable weight loss, though side effects may occur.
As January approaches, numerous individuals set New Year's resolutions focused on health and weight reduction goals. While exercise, gym visits, and nutritious diets support well-being and weight management, some may require additional help from medications. The NHS offers an important warning for those using Mounjaro injections alongside contraception or HRT.
